(Q53961500)

23 May 2018

title

Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. (English)

1 reference

23 May 2018

author name string

Topkis S

1

1 reference

23 May 2018

Swarz H

2

1 reference

23 May 2018

Breisch SA

3

1 reference

23 May 2018

Maroli AN

4

1 reference

23 May 2018

publication date

1 September 1997

1 reference

23 May 2018

published in

Clinical Therapeutics

1 reference

23 May 2018

volume

19

1 reference

23 May 2018

issue

5

1 reference

23 May 2018

page(s)

975-988

1 reference

23 May 2018

Community-acquired pneumonia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

A Guide to the Treatment of Lower Respiratory Tract Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

In vitro activity of OPC-17116

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980050-1

7 January 2021

10.1016/S0149-2918(97)80050-1

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018